Inflammation and cancer: Advances and new agents

Nature Reviews Clinical Oncology

Volumn 12, Issue 10, 2015, Pages 584-596

  Crusz, Shanthini M ^a   Balkwill, Frances R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMG 820; ANTIINFLAMMATORY AGENT; BORTEZOMIB; CARLUMAB; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CP 870893; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; EMACTUZUMAB; ETANERCEPT; IMC CS 4; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PACRITINIB; PLERIXAFOR; PLX 3397; REPARIXIN; RUXOLITINIB; SILTUXIMAB; TASQUINIMOD; TOCILIZUMAB; TRABECTEDIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; DRUG TARGETING; GIANT CELL TUMOR; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KIDNEY CARCINOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MEDIATOR; MULTIPLE MYELOMA; MYELOFIBROSIS; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; SARCOMA; SOLID TUMOR; SYSTEMATIC REVIEW (TOPIC); CHEMOPROPHYLAXIS; DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOPREVENTION; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942292465     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.105     Document Type: Review

References (203)

1. Kundu, J. K., Surh, Y. J. Inflammation: gearing the journey to cancer. Mutat. Res. 659, 15-30 (2008).
2. Mantovani, A., Allavena, P., Sica, A., Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
3. Grivennikov, S. I., Karin, M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20, 65-71 (2010).
4. Coussens, L. M., Zitvogel, L., Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bulletScience 339, 286-291 (2013).
5. Masferrer, J. L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
6. Hwang, D., Scollard, D., Byrne, J., Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl Cancer Inst. 90, 455-460 (1998).
7. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G., Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73-78 (2000).
8. Tucker, O. N. et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59, 987-990 (1999).
9. Buckman, S. Y. et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19, 723-729 (1998).
10. Wolff, H. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997-5001 (1998).
11. Mohammed, S. I. et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59, 5647-5650 (1999).
12. Chan, G. et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59, 991-994 (1999).
13. Waddell, W. R., Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol. 24, 83-87 (1983).
14. Algra, A. M., Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527 (2012).
15. Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012)
16. Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
17. Cuzick, J. et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann. Oncol. 26, 47-57 (2015).
18. Gay, L. J., Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123-134 (2011).
19. Eberhart, C. E. et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188 (1994).
20. Gierach, G. L. et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 10, R38 (2008).
21. Salinas, C. A. et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 172, 578-590 (2010).
22. Liao, X. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596-1606 (2012).
23. Fraser, D. M., Sullivan, F. M., Thompson, A. M., McCowan, C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br. J. Cancer 111, 623-627 (2014).
24. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00003835?term=NCT00003835=1 (2013).
25. Ng, K. et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J. Natl Cancer Inst. 107, 345 (2015).
26. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01150045 (2013).
27. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00565708?term=NCT00565708&rank=1 (2015).
28. The Add Aspirin trial. addaspirintrial.org [online], http://www.addaspirintrial.org/(2015).
29. Dulak, J., Jozkowicz, A. Anti-angiogenic and anti inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Targets 5, 579-594 (2005).
30. Boudreau, D. M., Yu, O., Johnson, J. Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf. 9, 603-621 (2010).
31. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02161822?term=NCT02161822&rank=1 (2014).
32. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01821404?term=NCT01821404&rank=1 (2015).
33. Argiles, J. M., Busquets, S., Toledo, M., Lopez-Soriano, F. J. The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 263-268 (2009).
34. Trajkovic-Vidakovic, M., de Graeff, A., Voest, E. E., Teunissen, S. C. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit. Rev. Oncol. Hematol. 84, 130-148 (2012).
35. Leggas, M. et al. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother. Pharmacol. 63, 731-743 (2009).
36. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
37. Germano, G., Allavena, P., Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374-379, (2008).
38. Hanahan, D., Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
39. Argiles, J. M., Moore-Carrasco, R., Fuster, G., Busquets, S., Lopez-Soriano, F. J. Cancer cachexia: the molecular mechanisms. Int. J. Biochem. Cell Biol. 35, 405-409 (2003).
40. Szlosarek, P., Charles, K. A., Balkwill, F. R. Tumour necrosis factor-alpha as a tumour promoter. Eur. J. Cancer 42, 745-750 (2006).
41. Feldmann, M., Maini, R. N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught usJ. Immunol. 185, 791-794 (2010).
42. Sandborn, W. J., Hanauer, S. B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5, 119-133 (1999).
43. Knight, D. M. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443-1453 (1993).
44. Mohler, K. M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561 (1993).
45. Wiens, A., Correr, C. J., Venson, R., Otuki, M. F., Pontarolo, R. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol. Int. 30, 1063-1070 (2010).
46. Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
47. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371 (2009).
48. Szlosarek, P. W. et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol. Cancer Ther. 5, 382-390 (2006).
49. Miles, D. W. et al. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int. J. Cancer 56, 777-782 (1994).
50. Balkwill, F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409-416 (2006).
51. Harrison, M. L. et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542-4549 (2007).
52. Larkin, J. M. et al. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br. J. Cancer 103, 1149-1153 (2010).
53. Wu, C. et al. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 42, 813-818 (2013).
54. Sheen-Chen, S. M., Chen, W. J., Eng, H. L., Chou, F. F. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res. Treat. 43, 211-215 (1997).
55. Madhusudan, S. et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10, 6528-6534 (2004).
56. Naylor, M. S., Stamp, G. W., Foulkes, W. D., Eccles, D., Balkwill, F. R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 91, 2194-2206 (1993).
57. Hassan, M. I., Kassim, S. K., Saeda, L., Laban, M., Khalifa, A. Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res. 19, 5657-5662 (1999).
58. Madhusudan, S. et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950-5959 (2005).
59. Wolfe, F., Michaud, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 56, 2886-2895 (2007).
60. Wolfe, F., Michaud, K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56, 1433-1439 (2007).
61. Askling, J. et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414-1420, (2005).
62. Askling, J. et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1421-1426 (2005).
63. Mariette, X. et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann. Rheum. Dis. 70, 1895-1904 (2011).
64. Leombruno, J. P., Einarson, T. R., Keystone, E. C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68, 1136-1145 (2009).
65. Askling, J. et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20, 119-130 (2011).
66. Moulis, G. et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS ONE 7, e48991 (2012).
67. Taniguchi, K., Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54-74 (2014).
68. Ancrile, B., Lim, K. H., Counter, C. M. Oncogenic RAS-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714-1719 (2007).
69. Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991).
70. Stone, R. L. et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366, 610-618 (2012).
71. Kulbe, H. et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585-592 (2007).
72. Anglesio, M. S. et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 17, 2538-2548 (2011).
73. Shain, K. H. et al. ?1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69, 1009-1015 (2009).
74. Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007).
75. van Zaanen, H. C. et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 102, 783-790 (1998).
76. Kurzrock, R. et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res. 19, 3659-3670 (2013).
77. Orlowski, R. Z. et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 90, 42-49 (2015).
78. Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083-6096 (2011).
79. Dorff, T. B. et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 16, 3028-3034 (2010).
80. Borsellino, N., Belldegrun, A., Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55, 4633-4639 (1995).
81. Hudes, G. et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs 31, 669-676 (2013).
82. Fizazi, K. et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur. J. Cancer 48, 85-93 (2012).
83. Rossi, J. F. et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010).
84. Ando, K. et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31, e69-e72 (2013).
85. Milagre, C. S. et al. Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL-6 antibodies with implications for combined therapy in ovarian cancer. Cancer Res. 75, 1255-1264 (2015).
86. Zhang, J., Patel, L., Pienta, K. J. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog. Mol. Biol. Transl. Sci. 95, 31-53 (2010).
87. Sandhu, S. K. et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 71, 1041-1050 (2013).
88. Pienta, K. J. et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest. New Drugs 31, 760-768 (2013).
89. Bonapace, L. et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130-133 (2014).
90. Tomimatsu, S., Ichikura, T., Mochizuki, H. Significant correlation between expression of interleukin-1and liver metastasis in gastric carcinoma. Cancer 91, 1272-1276 (2001).
91. Singer, C. F. et al. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1protein secretion is correlated with malignant phenotype. Clin. Cancer Res. 9, 4877-4883 (2003).
92. Ling, J. et al. KrasG12D-induced IKK2/?/NF-?B activation by IL-1and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21, 105-120 (2012).
93. Hong, D. S. et al. MABp1, a first-in-class true human antibody targeting interleukin-1in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 15, 656-666 (2014).
94. Oppenheim, J. J., Zachariae, C. O., Mukaida, N., Matsushima, K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol. 9, 617-648 (1991).
95. Larsen, C. G., Anderson, A. O., Appella, E., Oppenheim, J. J., Matsushima, K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243, 1464-1466 (1989).
96. Schroder, J. M., Sticherling, M., Henneicke, H. H., Preissner, W. C., Christophers, E. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J. Immunol. 144, 2223-2232 (1990).
97. Krieger, M. et al. Activation of human basophils through the IL-8 receptor. J. Immunol. 149, 2662-2667 (1992).
98. Wang, J. M., Taraboletti, G., Matsushima, K., Van Damme, J., Mantovani, A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem. Biophys. Res. Commun. 169, 165-170 (1990).
99. Strieter, R. M. et al. Interleukin-8. A corneal factor that induces neovascularization. Am. J. Pathol. 141, 1279-1284 (1992).
100. Koch, A. E. et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801 (1992).
101. Schadendorf, D. et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 2667-2675 (1993).
102. Sanmamed, M. F. et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin. Cancer Res. 20, 5697-5707 (2014).
103. Lee, L. F. et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 164, 2769-2775 (2000).
104. Lee, L. F. et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 56, 1303-1308 (1996).
105. Bekes, E. M. et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am. J. Pathol. 179, 1455-1470 (2011).
106. Huang, S. et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161, 125-134 (2002).
107. Zhu, Y. M., Webster, S. J., Flower, D., Woll, P. J. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br. J. Cancer 91, 1970-1976 (2004).
108. Matsuo, Y. et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer 125, 1027-1037 (2009).
109. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00003835?term=NCT00003835&rank=1 (2013).
110. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02001974 (2015).
111. Ginestier, C. et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120, 485-497 (2010).
112. Müller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
113. Hall, J. M., Korach, K. S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol. Endocrinol. 17, 792-803 (2003).
114. Taichman, R. S. et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62, 1832-1837 (2002).
115. Zagzag, D. et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178-6188 (2005).
116. Kim, S. Y. et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastases 25, 201-211 (2008).
117. Geminder, H. et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 167, 4747-4757 (2001).
118. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
119. Stuelten, C. H. et al. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-and TGF-?. J. Cell Sci. 118, 2143-2153 (2005).
120. Jung, Y. et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 4, 1795 (2013).
121. Smith, M. C. et al. CXCR4 regulates growth of-both primary and metastatic breast cancer. Cancer Res. 64, 8604-8612 (2004).
122. Kim, M. et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 70, 10411-10421 (2010).
123. D'Alterio, C. et al. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol. Immunother. 61, 1713-1720 (2012).
124. Uchida, D. et al. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur. J. Cancer 47, 452-459 (2011).
125. Kajiyama, H. et al. Involvement of SDF-1?/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 122, 91-99 (2008).
126. Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212-20217 (2013).
127. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02179970 (2015).
128. Bromberg, J. STAT proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142 (2002).
129. Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807 (2012).
130. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787-798 (2012).
131. Younes, A. et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30, 4161-4167 (2012).
132. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02055781?term=pacritinib&rank=3 (2015).
133. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
134. Song, L., Rawal, B., Nemeth, J. A., Haura, E. B. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol. Cancer Ther. 10, 481-494 (2011).
135. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436 (2006).
136. DiDonato, J. A., Mercurio, F., Karin, M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400 (2012).
137. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
138. San Miguel, J. F. et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in-patients with previously untreated multiple myeloma. J. Clin. Oncol. 31, 448-455 (2013).
139. Goy, A. et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann. Oncol. 20, 520-525 (2009).
140. Hata, H. et al. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 81, 3357-3364 (1993).
141. Orlowski, R. Z. et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma [abstract]. J. Clin. Oncol. 30 (Suppl.), a8018 (2012).
142. San-Miguel, J. et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123, 4136-4142 (2014).
143. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
144. Fridman, W. H., Pages, F., Sautes-Fridman, C., Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
145. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
146. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
147. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
148. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
149. Bingle, L., Brown, N. J., Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002).
150. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
151. Condeelis, J., Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006).
152. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev Cancer 4, 71-78 (2004).
153. Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
154. D'Incalci, M. et al. Unique features of the mode of action of ET-743. Oncologist 7, 210-216 (2002).
155. Michaelson, M. D. et al. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 23, 1234-1240 (2012).
156. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00050427?term=NCT00050427&rank=1 (2011).
157. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01339754?term=NCT01339754&rank=1 (2014).
158. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02194231?term=NCT02194231&rank=1 (2015).
159. Allavena, P. et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65, 2964-2971 (2005).
160. Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249-262 (2013).
161. Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128-1141 (2013).
162. Xu, J. et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782-2794 (2013).
163. Priceman, S. J. et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1-receptor: combating tumor evasion of antiangiogenic therapy. Blood 115, 1461-1471 (2010).
164. Mok, S. et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74, 153-161 (2014).
165. Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846-859 (2014).
166. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01444404?term=NCT01444404&rank=1 (2014).
167. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01346358?term=NCT01346358&rank=1 (2014).
168. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01596751?term=NCT01596751&rank=1 (2015).
169. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02265536?term=NCT02265536&rank=1 (2015).
170. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01349036?term=NCT01349036&rank=1 (2015).
171. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01004861?term=NCT01004861&rank=1 (2015).
172. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01346358?term=NCT01346358&rank=1 (2014).
173. Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057-5069 (2014).
174. Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
175. Sotomayor, E. M. et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780-787 (1999).
176. Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774-779 (1999).
177. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
178. Beatty, G. L. et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19, 6286-6295 (2013).
179. Bjork, P. et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 7, e97 (2009).
180. Bratt, O. et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br. J. Cancer 101, 1233-1240 (2009).
181. Pili, R. et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 29, 4022-4028 (2011).
182. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01234311?term=NCT+01234311&rank=1 (2014).
183. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01732549?term=NCT+01732549&rank=1 (2014).
184. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01513733?term=NCT+01513733&rank=1 (2014).
185. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970 (2013).
186. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976 (2013).
187. Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862-870 (2004).
188. Burnette, B., Weichselbaum, R. R. Radiation as an immune modulator. Semin. Radiat. Oncol. 23, 273-280 (2013).
189. Roses, R. E., Datta, J., Czerniecki, B. J. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat. Res. 182, 211-218, (2014).
190. Milas, L. et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 64, 5074-5077 (2004).
191. Mason, K. A. et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. 11, 361-369 (2005).
192. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01637532?term=NCT01637532&rank=1 (2014).
193. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01767857?term=NCT01767857&rank=1 (2015).
194. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02001974?term=NCT02001974&rank=1 (2015).
195. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02179970?term=NCT02179970&rank=1 (2015).
196. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02055781?term=NCT02055781&rank=1 (2015).
197. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02277093?term=NCT02277093&rank=1 (2015).
198. Demetri, G. D. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27, 4188-4196 (2009).
199. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00002904?term=NCT00002904&rank=1 (2012).
200. US National Library Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01346358?term=NCT01346358&rank=1 (2014).
201. US National Library Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01444404?term=NCT01444404&rank=1 (2015).
202. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01004861?term=NCT01004861&rank=1 (2015).
203. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01234311?term=NCT01234311&rank=1 (2014).